National Academy of Medicine Elects Five Penn Experts
Five Penn experts have been elected to the National Academy of Medicine (NAM), one of the nation’s highest honors in the fields of health and medicine.
Penn biomedical scientists move into new uCity complex with 115,000 square feet of lab space
A group of Penn scientists and engineers is moving into 115,000 square feet of new lab space in the 13-story One uCity Square building in West Philadelphia.
Team members of I Corps Team and Penn President’s Prize Winner Sonura are Named Philadelphia Business Journal’s “Inno Under 25”
The group was named as 2023’s Inno Under 25 honorees by the Philadelphia Business Journal.
Katalin Karikó and Drew Weissman Named Co-Recipients of the 2023 Nobel Prize for Medicine
Penn’s Katalin Karikó, PhD, and Drew Weissman, MD, PhD, have been named winners of the 2023 Nobel Prize in Physiology or Medicine.
Mitchell Named “Young Innovator of Cellular and Molecular Bioengineering”
Mike Mitchell, PhD, J. Peter and Geri Skirkanich Assistant Professor of Innovation in Bioengineering (BE), was named a "Young Innovator of Cellular and Molecular Bioengineering."
New research from the Mitchell Lab offers a safer path for CAR T cell immunotherapy
The new method involves attaching a sugar molecule onto the surface of CAR T cells using metabolic labeling, a modification that enables the CAR T cells to attack cancer cells without any hindrance.
Carl June to receive the 2024 Breakthrough Prize in Life Sciences
June was awarded for the development of chimeric antigen receptor (CAR) T cell immunotherapy.
Bruce Levine Speaks on the Progress of CAR T at the 2023 CAR-TCR Summit
In this recorded event, which took place on the six-year anniversary of the first approved CAR-T Levine, discusses emerging technology trends that might improve CAR-T therapies.
Mitchell Lab develops a microchip designed to transform the production of mRNA therapeutics and vaccines
“This technology has the potential to become a cornerstone in the field of nanomedicine, beyond RNA-based therapies,” Mitchell said in the Penn Today article.
Apellis Receives FDA Approval for SYFOVRE™ (pegcetacoplan injection) as the First Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
Penn spinout Apellis Pharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for their drug SYFOVRE™ (pegcetacoplan injection).